September 30, 2024

Meta-analysis Finds Congenital Heart Disease Triples the Odds of ADHD in Children

Congenital heart disease (CHD) is a common birth defect where the heart’s blood vessels don’t develop normally before birth. This condition affects about 9% of all births worldwide, meaning about one in eleven babies is born with CHD. A recent analysis found that children with CHD have three times the risk of developing ADHD compared to children without CHD. However, that study only included five smaller studies, and almost 90% of the results varied between studies, making the findings less reliable. To improve on this, a team of researchers conducted a new, more thorough analysis.

Key Findings of the New Study

The updated analysis combined eleven studies, involving nearly 300,000 people. This larger study also confirmed that children with CHD are three times more likely to develop ADHD than those without CHD. Importantly, there was no evidence that the results were biased by only including studies that showed stronger results ("publication bias"). The variation between the studies (heterogeneity) was lower in this new analysis, down to a more manageable 60%.

Breaking Down the Study Types

The researchers looked at two types of studies: cohort studies and cross-sectional studies, and found different levels of risk:

  • Cohort studies: These studies followed groups of people over time. In this case, researchers compared children with CHD to those without it to see if ADHD developed later on. These five studies, with over 19,000 participants, found that children with CHD were 3.5 times more likely to develop ADHD.
  • Cross-sectional studies: These studies collected data at a single point in time, looking at children who already had CHD and checking if they had ADHD. The six cross-sectional studies, with more than 277,000 participants, found a lower, but still significant, 2.1 times higher risk of ADHD in children with CHD.

While both types of studies suggest a strong link between CHD and ADHD, cohort studies are more reliable because they track children over time, which helps researchers establish that CHD occurred before ADHD, suggesting a stronger cause-and-effect relationship. Both types of studies are observational.  In any observational study, researchers look at data without actively changing or controlling anything in the study environment. Because they aren't conducting controlled experiments, it's possible that some important factors, known as "confounding factors," aren't being measured or accounted for. These factors can influence both the exposure (what the study is investigating, like CHD) and the outcome (ADHD) in a way that creates an association that is apparent but not rea.

Adjustments for Other Factors

Nine of the studies, which included almost 300,000 participants, adjusted their findings to account for "confounding factors"—things like age, gender, or other health conditions that could also influence whether a child develops ADHD. Even after making these adjustments, the risk of ADHD in children with CHD was still three times higher.

Other Study Details

The researchers also found that the way ADHD was diagnosed—whether through clinical assessments or standardized symptom checklists—didn’t change the results much. Additionally, there was no major difference between studies done in the U.S. and those conducted in other countries, or between higher- and lower-quality studies.

Conclusion

The research team concluded that children born with congenital heart disease are at a much higher risk of developing ADHD than children without CHD. They suggested that children with CHD should be monitored more closely for ADHD as they grow up to ensure early intervention if needed.

‍

Jiapeng Tang, Jun Ou, Yige Chen, Liuxuan Li, Hanjun Liu, Mengting Sun, Manjun Luo, Taowei Zhong, Tingting Wang, Jianhui Wei, Qian Chen, and Jiabi Qin, “The risk of attention-deficit hyperactivity disorder among children with congenital heart disease: A systematic review and meta-analysis,” Child: Care, Health and Development (2024), vol. 50, issue 1, e13174, https://doi.org/10.1111/cch.13174.

Georges Choueiry, “Cohort vs Cross-Sectional Study: Similarities and Differences,” Quantifying Health, https://quantifyinghealth.com/cohort-vs-cross-sectional-study/.

‍

Related posts

No items found.

Swedish Nationwide Population Study: Little ADHD Risk from Vacuum-Assisted Delivery

Vacuum-assisted delivery (VAD), also called vacuum extraction, is an assisted vaginal birth method in which a soft plastic cup is attached to the baby’s head with suction to help guide the infant through the birth canal during the pushing stage. Clinicians typically use VAD when labor stalls, the mother is exhausted, or there are concerns about the baby’s heart rate. It is an alternative to a cesarean section (C‑section) that can avoid major surgery. 

In Sweden, VAD is used in about 6%–9% of births, while forceps deliveries are uncommon. When performed with the fetal head at the outlet station (very low in the birth canal), VAD is usually quick and carries minimal risk of injury in full-term babies; these outlet procedures make up roughly half of all VADs. By contrast, several studies have linked VAD performed at mid or low fetal head stations with more serious neonatal complications, such as intracranial bleeding, seizures and, in rare cases, death. 

Despite concerns about short-term neonatal injury after mid/low VAD, research on long-term neurodevelopmental outcomes is limited. A few more recent studies have not found clear links between VAD and adverse long-term outcomes, but most of those studies did not separate outlet from mid/low procedures. 

To address this gap, the authors conducted a nationwide, population-based study in Sweden to compare neonatal and long-term neurodevelopmental outcomes after VAD, and to stratify results by fetal station. They included emergency cesarean delivery and spontaneous vaginal delivery as reference groups to help interpret outcomes after VAD. 

The study used Sweden’s linked national registers, possible because every resident has a personal identification number. Sweden’s tax-funded single-payer health system and nearly universal hospital births mean the registers provide comprehensive, standardized data suitable for long-term follow-up. 

The cohort comprised 630,985 singleton term births from 1997 through 2014. Of these, 73,215 (11.6%) were delivered by VAD, 73,739 (11.7%) by emergency cesarean delivery, and 484,031 (76.7%) by spontaneous vaginal delivery. Among the VAD births, 31,014 (42.4%) were classified as mid/low station and 42,201 (57.6%) as outlet VAD. 

The investigators adjusted their analyses for potential confounders including maternal age; early-pregnancy body-mass index; smoking during pregnancy; the child’s birth year; preeclampsia; gestational diabetes; chorioamnionitis; maternal education level; and maternal medical or psychiatric conditions (type 1 or type 2 diabetes, ADHD, autism spectrum disorder, depression and anxiety). 

After adjustment, VAD overall was associated with a 6% lower risk of later being diagnosed with ADHD compared with the reference groups. When broken down by fetal station, mid/low VAD showed no difference in ADHD risk, while outlet VAD was associated with a 9% lower risk. For comparison, spontaneous vaginal delivery was associated with a 12% lower risk of later ADHD. 

The authors concluded that, in this large nationwide cohort, the findings may offer reassuring evidence about the overall long-term neurodevelopmental safety of VAD.  

‍

‍

‍

Meta-analysis: Almost Three in Four ADHD Patients Receive Pharmaceutical Treatment

The Background:

Management of ADHD relies on both medications and non-medication approaches. Clinical guidelines often recommend medication as the first-line treatment for adults, while non-medication interventions are often preferred for children. Medicines fall into two main groups: stimulants (for example, methylphenidate and amphetamines), which have strong and well-established evidence and are generally considered first choice, and non-stimulants (such as atomoxetine), which are typically used when stimulants are contraindicated, not tolerated, or ineffective. 

How many people with ADHD receive medication is an important indicator of care quality and can be tracked at the national level. Untreated ADHD can affect many areas of life, from physical health, to school and work performance, to relationships emotional well-being. ADHD is associated with poorer quality of life, higher risk of accidents, substance use issues, criminal behavior, educational underachievement, and even increased premature mortality. The condition also places a substantial burden on families and caregivers, so understanding treatment rates matters for individuals and society. 

Most epidemiological research has measured how common diagnosed ADHD is, but the share of those diagnosed who actually receive medication can vary a lot. That variation reflects differences in how ADHD is diagnosed, how easy it is to get treatment, what clinical guidelines recommend, and cultural attitudes toward using medication. 

The Study:

This paper presents the first comprehensive meta-analysis to estimate how common pharmacological treatment is among children, adolescents, and adults with clinically confirmed ADHD. The analysis included only register-based population studies where diagnoses were confirmed by a qualified healthcare professional. Twelve studies meeting these criteria from Europe (the UK, Sweden, Denmark), Asia (Taiwan, South Korea), and North America (Canada, the United States) were used. Notably, these are all high-income areas, and thus unrepresentative of populations in lower-income countries.  

The pooled estimate showed that about 73 percent of diagnosed individuals in prosperous parts of the world with well-developed health care systems were receiving medication, but there was very high variation between studies. 

The Results:

The authors conclude there is substantial global variation in ADHD medication use. Overall, a relatively high proportion of people diagnosed with ADHD are treated with medication, which may reflect improved recognition and access to care. The large differences between studies probably reflect differing health systems, diagnostic rules, treatment definitions, study populations, and reporting practices, and they underline the need for more standardized definitions and reporting to make comparisons more meaningful.  

There is also a need for information from lower-income regions, but that is complicated by an absence of register-based population studies in countries with more limited health care access.

‍

November 4, 2026

Meta-analysis Finds Three- to Eight-fold Higher ADHD Prevalence Among Adults with Substance Use Disorders

The Background:

Because impulsivity is a core feature of ADHD, researchers have suggested it may raise the likelihood that someone will use psychoactive substances (including alcohol) and go on to develop a substance use disorder (SUD). When ADHD and SUD occur together in adolescents, treating one disorder alone usually has little or no positive effect on the other; current guidance therefore recommends treating both conditions at the same time using evidence-based approaches for each. 

Given how much ADHD can worsen outcomes for people with primary SUDs, it is important to identify ADHD in people who are being treated for substance problems. 

The Study:

A recent systematic meta-review found that, by current official criteria, ADHD affects about 7.2% of children and adolescents and about 2.6% of adults (Chaulagain et al., 2023). When adult ADHD is defined without the requirement that symptoms began by age 11, roughly 6.8% of adults meet criteria. A large body of research links ADHD to higher rates of medical problems, poorer quality of life, greater risk of suicide, more accidental injuries, worse educational outcomes, and increased involvement with the criminal justice system. 

The present study is the first meta-analysis to estimate how common clinically diagnosed ADHD is among adults (age 18+) who are in treatment for psychoactive substance use disorders, and to provide those estimates by sex and by the specific substance used. 

The authors included only studies of adults treated for a SUD (including alcohol). Eighty-four studies met the criteria, representing more than 34,000 people. Across all studies, the pooled prevalence of clinically diagnosed ADHD was 22%. 

To put that in context, 22% is about eight times higher than the 2.6% adult prevalence using the stricter official definition, and about three times higher than the 6.8% rate when the childhood-onset requirement is relaxed. By substance, the prevalence was similar for alcohol (24%) and opioids (22%), with no significant difference between males and females. Prevalence among people treated for cocaine use was somewhat lower overall (18%), driven largely by lower rates among women, for whom the rate was no higher than in the general population. Estimates were higher for people using benzodiazepines and cannabis, but those figures are based on a very small number of users (256 and 249 people, respectively) and are therefore less certain. 

The Results: 

The authors conclude: “These findings underscore the need for early identification and treatment of ADHD as most substance use disorders develop in adolescence and young adulthood. While in treatment for ADHD, appropriate screening and management of substance use is possible.” 

‍

October 29, 2026